王咏,胡蓉蓉,李芳
WANG Yong,HU Rongrong,LI Fang

• 1:江苏医药职业学院
• 2:东南大学附属中大医院

摘要(Abstract)：

目的 探索微小核糖核酸(miRNA)miR-96-5p通过调控肌动蛋白结合蛋白1(profilin 1,PFN1)对卵巢癌干细胞(SiHa细胞)顺铂耐药的分子机制。方法 采用RT-qPCR检测miR-96-5p表达水平；将SiHa细胞置于不同浓度顺铂的培养基中，构建顺铂耐药细胞SiHa/DDP;采用Western blot检测蛋白的表达水平；双荧光素酶报告实验验证miR-96-5p与PFN1的靶向关系；MTT、Transwell和流式细胞术检测细胞增殖、侵袭和凋亡；成球实验检测细胞的成球能力。结果 miR-96-5p在SiHa细胞中高表达，且在SiHa/DDP细胞中的表达最高；敲降miR-96-5p可抑制SiHa/DDP细胞增殖、侵袭和干细胞成球能力并促进细胞凋亡；PFN1是miR-96-5p的潜在靶基因，过表达miR-96-5p通过下调PFN1促进SiHa/DDP细胞增殖、侵袭和干细胞成球，抑制细胞凋亡。结论 miR-96-5p通过靶向调控PFN1,促进SiHa/DDP细胞增殖、侵袭及其干细胞成球并抑制凋亡，从而增强SiHa/DDP细胞对顺铂的耐药性。
Objective To explore the molecular mechanism of the effect of microRNA(miR-96-5p)on ovarian cancer stem cells cisplatin resistance through profilin 1(PFN1).Methods The expression level of miR-96-5p was detected by RT-qPCR.SiHa cells were cultured in medium supplemented with various concentrations of cisplatin to construct cisplatin resistant SiHa/DDP.The expression levels of protein were detected by Western blot.The targeting relationship between miR-96-5p and PFN1 was verified by the dual-luciferase reporter gene experiment.Proliferation, invasion and apoptosis levels of SiHa/DDP cells were measured by MTT,Transwell and flow cytometry.Cell blasting assay was used to detect the globing ability of cells.Results miR-96-5p was highly expressed in SiHa cells, and the highest expression level was found in SiHa/DDP cells.Knockdown of miR-96-5p could inhibit SiHa/DDP cells proliferation, invasion and promote cell apoptosis.PFN1 was a potential target gene of miR-96-5p.Overexpression of PFN1 could promote SiHa/DDP cell proliferation, invasion, stem cell pellet and inhibition of apoptosis.Conclusion miR-96-5p promotes proliferation, invasion, stem cell pellet of stem cells and inhibits apoptosis of SiHa/DDP cells by targeting negative regulation of PFN1,thereby enhancing the drug resistance of SiHa/DDP cells to cisplatin.

关键词(KeyWords)： 卵巢癌;干细胞;miR-96-5p;肌动蛋白结合蛋白1;增殖;侵袭;凋亡
ovarian cancer;stem cell;miR-96-5p;profilin 1;proliferation;invasion;apoptosis

Abstract:

Keywords:

基金项目(Foundation): 江苏省自然科学基金资助项目(BK20180273);; 江苏高等学校A类品牌药学专业建设项目(PPZY2015A097)

作者(Author): 王咏,胡蓉蓉,李芳
WANG Yong,HU Rongrong,LI Fang

DOI: 10.14066/j.cnki.cn21-1349/r.2021.1232

参考文献(References)：

• [1] MUKHERJEE B,TOWER S.A comprehensive gene-environment interaction analysis in ovarian cancer using genome-wide significant common variants [J].Int J Cancer,2019,9(144):2192-2205.
• [2] QIN Y,LI W,LONG Y,et al.Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis [J].Cancer Biomark,2019,24(4):469-475.
• [3] SRIVASTAVA A K,HAN C,ZHAO R,et al.Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells [J].Pnas,2015,112(14):4411.
• [4] LIU W,WANG S,ZHOU S,et al.A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells [J].Mol Biosyst,2017,13(11):2268-2276.
• [5] LIU B,ZHANG J,YANG D.miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1 [J].J Ovarian Res,2019,12(1):57.
• [6] CHANG J,DING Z,JOY M,et al.A balanced level of profilin-1 promotes stemness and tumor-initiating potential of breast cancer cells [J].Cell Cycle,2017,16(24):2366-2373.
• [7] CHAKRABORTY S,JIANG C,GAU D,et al.Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells [J].Brit J Cancer,2018,119(9):1106-1117.
• [8] ZHANG X Y,ZHANG M,CONG Q,et al.Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy [J].Int J Biochem Cell B,2018,95:9-16.
• [9] JIN P,LIU Y,WANG R.STAT3 regulated microRNA-216a promotes ovarian cancer proliferation and cisplatin resistance [J].Bioscience Rep,2018,38(4):BSR20180547.
• [10] SAYDAMINOVA K,STRAUSS R,XIE M,et al.Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells [J].Cancer Biol Ther,2016,17(10):1079-1088.
• [11] CHOI E J,SEO E J,KIM D K,et al.FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells [J].Oncotarget,2016,7(3):3506-3519.
• [12] MIRNA M,PAAR V,REZAR R,et al.microRNAs in inflammatory heart diseases and sepsis-induced cardiac dysfunction:a potential scope for the future?[J].Cells,2019,8(11):1352.
• [13] B J Y J A,B H K A,B T H K A,et al.microRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3 [J].Cancer Lett,2017,386:168-178.
• [14] WANG X,MENG Q,QIAO W,et al.miR-181b/Notch2 overcome chemoresistance by regulating can-cer stem cell-like properties in NSCLC [J].Stem Cell Res Ther,2018,9(1):327.
• [15] RESS A L,STIEGELBAUER V,WINTER E,et al.miR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients [J].Mol Carcinogen,2015,54(11):1442-1450.
• [16] ASSAL,AMR R,TAYEBI,et al.A pleiotropic effect of the single clustered hepatic metastamirs miR-96-5p and miR-182-5p on insulin-like growth factor II,insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma [J].Mol Med Rep,2015,12(1):645-650.
• [17] VAHABI M,PULITO C,SACCONI A,et al.miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells [J].J Exp Clin Canc Res,2019,38(1):141.
• [18] YAO W,YU X,FANG Z,et al.Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin β1-actin complex in breast cancer cells [J].J Cell Mol Med,2012,16(4):824-835.
• [19] YA W,YANG W,RONGJUN W,et al.Profilin 1 protein and its implications for cancers [J].Oncology,2021,35(7):402-409.
• [20] YAO W,JI S,QIN Y,et al.Profilin 1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis [J].Mol Cancer,2014,13(1):187.
• [21] YICHEN L,YA W,HE X,et al.Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma [J].Cancer Sci,2018,109(9):2706-2716.